PE-22-28 vs Selank
Emerging vs Well Studied
synergistic Different mechanisms for anxiety and mood support.
Molecular Data
PE-22-28 Selank
Weight 773.89 Da 751.89 Da
Half-life Approximately 23 hours 2-10 minutes
Chain 7 amino acids 7 amino acids
Type Linear heptapeptide Tuftsin analog
Key Benefits
PE-22-28
01 Rapid antidepressant effects within 4 days (preclinical)
02 Hippocampal neurogenesis and synaptogenesis
03 Enhanced serotonergic neurotransmission
04 Extended ~23 hour duration of action
05 300-500x greater potency than full-length Spadin
Selank
01 Rapid onset anxiolytic effects
02 Enhanced BDNF expression (30% increase)
03 Improved stress resilience
04 Cognitive enhancement
05 Immune modulation
06 No tolerance or withdrawal
07 Neuroprotective effects
Dosing Protocols
PE-22-28
50-200mcg daily / Once daily
Antidepressant Effect 50-200mcg Once daily
Neurogenesis Support 100-200mcg Once daily
Selank
250-500mcg per dose / 1-2x daily (morning and/or evening)
Mild anxiety relief 250mcg 1x daily
Moderate anxiety/cognitive 250mcg 2x daily (morning & evening)
Intensive anxiety support 500mcg 1x daily (divided doses)
Cognitive enhancement 250-350mcg 1x daily (morning)
PTSD support 250mcg 2x daily
Immune support 250mcg 1x daily for 2-4 weeks
Side Effects
PE-22-28
No effects on TREK-2, TRAAK, TASK-1 channels observed
No cardiac dysfunction or seizures in preclinical studies
Selank
Minimal side effects - excellent safety profile
No sedation or cognitive impairment
No tolerance, dependence, or withdrawal
Contraindications
Pregnancy and breastfeeding
Concurrent MAOI use
Known peptide allergies
Pregnancy or breastfeeding
Consult healthcare provider with multiple psychiatric medications
Research Evidence
PE-22-28 Selank
Status Emerging Well Studied
References 3 studies 4 studies
Latest — March 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.